Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

OBJECTIVE: The objective of this study was to evaluate the efficacy, tolerability, and safety of 120 mg DFN‐15 vs placebo for the acute treatment of migraine. BACKGROUND: Certain nonsteroidal anti‐inflammatory drugs (NSAIDs) are guideline‐recommended therapies for the acute treatment of migraine, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Munjal, Sagar, Brand‐Schieber, Elimor, Tepper, Stewart J., Dodick, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003821/
https://www.ncbi.nlm.nih.gov/pubmed/31647577
http://dx.doi.org/10.1111/head.13663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003821/
https://www.ncbi.nlm.nih.gov/pubmed/31647577
http://dx.doi.org/10.1111/head.13663

Ejemplares similares